In light of the strong desire to shorten timelines and lower cost for biologics such as monoclonals specially biosimilars, and address surging demand for complex proteins such as bispecific antibodies ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Human cell and tissue products pass through either a ...

Explore how parenteral manufacturing solutions are evolving for specific drug formulations and meeting the demands of ...

Before the advent of biologics, commercialization of a therapeutic relied on successfully scaling up to meet market demand. This scaling-up strategy expanded biomanufacturing capacity by upsizing the ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- C3 AI (NYSE: AI), the Enterprise AI application software company, today announced that Genentech, the medical biotechnology company, has selected C3 AI ...

WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture. The platform can significantly ...

Dublin, March 02, 2026 (GLOBE NEWSWIRE) -- The "Continuous Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Drug Molecule, Stage of Bioprocessing, Type ...

ADMA Biologics receives FDA approval for a process enhancing plasma production yields by 20%, boosting growth and capacity for its products. ADMA Biologics, Inc. has announced the U.S. FDA approval of ...

As global uncertainty grows, biotech and biopharma companies are rethinking manufacturing strategies to reduce risk and ensure continuity. Onshoring drug substance development for biologics offers a ...

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ...

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics today announced a growth equity investment of $22.5 million from Great Point Partners, LLC, a Greenwich, Connecticut private investment firm focused ...